Clinical Trials for Oral, Inhaled and Intravenous Drug Delivery System for Lung Cancer and Emerging Nanomedicine-Based Approaches

References

• Chhikara BS, Parang K. Global cancer statistics 2022: the trends projection analysis. Chem Biol Lett. 2023;10(1):451.
   Web of Science ®Google Scholar
• Sabarwal A, Kumar K, Singh RP. Hazardous effects of chemical pesticides on human health–cancer and other associated disorders. Environ Toxicol Pharmacol. 2018;63:103–114. doi:10.1016/j.etap.2018.08.018
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015;112(1):S6–13. doi:10.1038/bjc.2015.30
   PubMedGoogle Scholar
• Huang CY, Ju DT, Chang CF, Reddy PM, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer. Biomedicine. 2017;7(4). doi:10.1051/bmdcn/2017070423
   Google Scholar
• Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;Volume 11:943–953. doi:10.2147/CMAR.S187317
   Google Scholar
• Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:193. doi:10.3389/fonc.2017.00193
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–566. doi:10.1016/j.ctrv.2013.10.001
   PubMed Web of Science ®Google Scholar
• Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–72. doi:10.1016/S1470-2045(14)71180-5
   PubMed Web of Science ®Google Scholar
• Niveria K, Yadav M, Dangi K, Verma AK. Overcoming challenges to enable targeting of metastatic breast cancer tumour microenvironment with nano-therapeutics: current status and future perspectives. OpenNano. 2022;8:100083. doi:10.1016/j.onano.2022.100083
   Google Scholar
• Rieger H, Welter M. Integrative models of vascular remodeling during tumor growth. Wiley Interdiscip Rev Syst Biol Med. 2015;7(3):113–129. doi:10.1002/wsbm.1295
   PubMed Web of Science ®Google Scholar
• Awad NS, Salkho NM, Abuwatfa WH, Paul V, AlSawaftah NM, Husseini GA. Tumor vasculature vs tumor cell targeting: understanding the latest trends in using functional nanoparticles for cancer treatment. OpenNano. 2023;11:100136. doi:10.1016/j.onano.2023.100136
   Google Scholar
• Singh L, Nair L, Kumar D, et al. Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival. Front Oncol. 2023;13:1034205. doi:10.3389/fonc.2023.1034205
   PubMed Web of Science ®Google Scholar
• Calvin JR, Sanderlin EJ, Yang LV. Molecular connections between cancer cell metabolism and the tumor microenvironment. Int J Mol Sci. 2015;16(5):11055–11086.
   PubMed Web of Science ®Google Scholar
• Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020;10:397. doi:10.3389/fonc.2020.00397
   PubMed Web of Science ®Google Scholar
• Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13(71):287–297.
   PubMed Web of Science ®Google Scholar
• Little AG. No nodes is good nodes. the annals of thoracic surgery. Ann Thorac Surg. 2006;82(1):4–5. doi:10.1016/j.athoracsur.2006.03.051
   PubMedGoogle Scholar
• Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622. doi:10.1016/j.mayocp.2019.01.034
   PubMed Web of Science ®Google Scholar
• Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015;1856(2):189–210. doi:10.1016/j.bbcan.2015.08.002
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non–small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330–353. doi:10.1200/JCO.2004.09.053
   PubMed Web of Science ®Google Scholar
• Hamid R, Manzoor I. Nanomedicines: nano based drug delivery systems challenges and opportunities. Altern Med. 2021;27:59.
   Google Scholar
• Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055. doi:10.3390/biomedicines10092055
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer. 2001;34(3):427–432. doi:10.1016/S0169-5002(01)00278-1
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Delivery Rev. 2014;66:2–5. doi:10.1016/j.addr.2013.11.009
   PubMed Web of Science ®Google Scholar
• Landi L, Rossi A. Cetuximab in the treatment of advanced non-small cell lung cancer: fISHing for a miraculous catch. J Thorac Dis. 2018;10(Suppl 17):S1940. doi:10.21037/jtd.2018.04.126
   PubMedGoogle Scholar
• Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13(6):745–758. doi:10.1586/era.13.47
   PubMed Web of Science ®Google Scholar
• Master AM, Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine. 2012;7(12):1895–1906. doi:10.2217/nnm.12.160
   PubMed Web of Science ®Google Scholar
• Bajracharya R, Song JG, Patil BR, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 2022;29(1):1959–1970. doi:10.1080/10717544.2022.2089296
   PubMed Web of Science ®Google Scholar
• Subhan MA, Yalamarty SS, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via EPR effect for cancer treatment. J Pers Med. 2021;11(6):571. doi:10.3390/jpm11060571
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjugate Chem. 2016;27(10):2225–2238. doi:10.1021/acs.bioconjchem.6b00437
   PubMed Web of Science ®Google Scholar
• Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. doi:10.3390/jpm11080771
   PubMed Web of Science ®Google Scholar
• Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85–98. doi:10.1016/j.nantod.2019.02.005
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu W, Tian Y, et al. Anti-EGFR peptide-conjugated triangular gold nanoplates for computed tomography/photoacoustic imaging-guided photothermal therapy of non-small cell lung cancer. ACS Appl Mater Interfaces. 2018;10(20):16992–17003. doi:10.1021/acsami.7b19013
   PubMed Web of Science ®Google Scholar
• Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48.
   PubMedGoogle Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52. doi:10.3390/cancers9050052
   PubMed Web of Science ®Google Scholar
• Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences. Crit Rev Oncol Hematol. 2007;62(1):53–61. doi:10.1016/j.critrevonc.2006.12.008
   PubMed Web of Science ®Google Scholar
• Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy. 2010;6(8):1066–1077. doi:10.4161/auto.6.8.13366
   PubMed Web of Science ®Google Scholar
• Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J. 2012;448(Pt 3):417. doi:10.1042/BJ20121513
   PubMedGoogle Scholar
• Cavallaro S. CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci. 2013;14(1):1713–1727. doi:10.3390/ijms14011713
   PubMed Web of Science ®Google Scholar
• Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non-small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 2013;3(1):26. doi:10.7150/thno.4922
   PubMed Web of Science ®Google Scholar
• Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009;15(23):7299–7308. doi:10.1158/1078-0432.CCR-09-1745
   PubMed Web of Science ®Google Scholar
• Estelrich J, Sánchez-Martín MJ, Busquets MA. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomed. 2015;10:1727. doi:10.2147/IJN.S76501
   PubMed Web of Science ®Google Scholar
• Desai A, Abdayem P, Adjei AA, Planchard D. Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer. 2022;163:96–106. doi:10.1016/j.lungcan.2021.12.002
   PubMed Web of Science ®Google Scholar
• Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. doi:10.1038/s41392-022-00947-7
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089
   PubMedGoogle Scholar
• Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the Phase II TRINITY StudyPhase II Study results of Rova-T in DLL3-expressing SCLC. Clin Cancer Res. 2019;25(23):6958–6966. doi:10.1158/1078-0432.CCR-19-1133
   PubMed Web of Science ®Google Scholar
• Carbone DP, Morgensztern D, Le Moulec S, et al. Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. 2018:8507–8507.
   Google Scholar
• Su WP, Chang LC, Song WH, et al. Polyaniline-based random-condensation on Au nanoparticles enhances immunotherapy in lung cancer. ACS Appl Mater Interfaces. 2022;14(21):24144–24159. doi:10.1021/acsami.2c03839
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974. doi:10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017;6(2):196. doi:10.21037/tlcr.2017.03.01
   PubMed Web of Science ®Google Scholar
• Chen SJ, Wang SC, Chen YC. Immunotherapy for colorectal cancer, lung cancer and pancreatic cancer. Int J Mol Sci. 2021;22(23):12836. doi:10.3390/ijms222312836
   PubMed Web of Science ®Google Scholar
• Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50(5):600–613.
   PubMed Web of Science ®Google Scholar
• Patwa A, Shah A. Anatomy and physiology of respiratory system relevant to anaesthesia. Indian J Anaesth. 2015;59(9):533–541. doi:10.4103/0019-5049.165849
   PubMed Web of Science ®Google Scholar
• Ochs M, Nyengaard JR, Jung A, et al. The number of alveoli in the human lung. Am J Respir Crit Care Med. 2004;169(1):120–124. doi:10.1164/rccm.200308-1107OC
   PubMed Web of Science ®Google Scholar
• Dhand C, Prabhakaran MP, Beuerman RW, Lakshminarayanan R, Dwivedi N, Ramakrishna S. Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery. RSC Adv. 2014;4(62):32673–32689. doi:10.1039/C4RA02861A
   Web of Science ®Google Scholar
• Patil JS, Sarasija S. Pulmonary drug delivery strategies: a concise, systematic review. Lung India. 2012;29(1):44–49. doi:10.4103/0970-2113.92361
   PubMedGoogle Scholar
• Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018 ;2018:1–11. doi:10.1155/2018/2732017
   Web of Science ®Google Scholar
• Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129. doi:10.3390/pharmaceutics11030129
   PubMed Web of Science ®Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;24:1609–1621.
   Google Scholar
• Arafat M. Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review. Int J Pharm Pharm Sci. 2015;7(7):16–21.
   Google Scholar
• Bordonaro S, Vizzini L, Spinnato F, et al. Oral chemotherapy in elderly patients with advanced non-small cell lung carcinoma. WCRJ. 2014;1(2):E223.
   Google Scholar
• Guetz S, Tufman A, von Pawel J, et al. Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine–a Phase I trial. Onco Targets Ther. 2017;10:1081. doi:10.2147/OTT.S122106
   PubMed Web of Science ®Google Scholar
• Crinò L, Calandri C, Maestri A, Marrocolo F. Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. Oncology . 2001;15(3 Suppl 6):40–42.
   PubMed Web of Science ®Google Scholar
• Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomized multinational phase III study alternating oral and iv vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009;20(7):1249–1256. doi:10.1093/annonc/mdn774
   PubMed Web of Science ®Google Scholar
• Xie M, Chen X, Qin S, Bao Y, Bu K, Lu Y. Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. J Cancer Res Ther. 2018;14(1):226–232. doi:10.4103/0973-1482.188436
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2015;372(18):1700–1709. doi:10.1056/NEJMoa1413654
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8062. doi:10.1200/jco.2015.33.15_suppl.8062
   Web of Science ®Google Scholar
• Lin SH, Lin HY, Verma V, et al. Phase I trial of definitive concurrent chemoradiotherapy and trametinib for KRAS-mutated non-small cell lung cancer. Cancer Treat Res Commun. 2022;30:100514. doi:10.1016/j.ctarc.2022.100514
   PubMedGoogle Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomized, phase 3 trials. Lancet Oncol. 2015;16(2):141–151. doi:10.1016/S1470-2045(14)71173-8
   PubMed Web of Science ®Google Scholar
• Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244. doi:10.1200/JCO.2018.78.7994
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi:10.1056/NEJMoa2027187
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–270. doi:10.1016/S1470-2045(19)30690-4
   PubMed Web of Science ®Google Scholar
• Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411. doi:10.3389/fphar.2021.618411
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362–372. doi:10.1093/jnci/95.5.362
   PubMed Web of Science ®Google Scholar
• Lerouge D, Rivière A, Dansin E, et al. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 2014;14(1):1–9. doi:10.1186/1471-2407-14-231
   PubMedGoogle Scholar
• Ding L, Li QJ, You KY, Jiang ZM, Yao HR. The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine. 2016;95(20):e3598. doi:10.1097/MD.0000000000003598
   PubMed Web of Science ®Google Scholar
• Chang JW, Huang CY, Fang YF, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: real‐world data from Taiwan. Thoracic Cancer. 2023;14(1):12–23. doi:10.1111/1759-7714.14537
   PubMed Web of Science ®Google Scholar
• Helena AY, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013;11(2):161–169. doi:10.6004/jnccn.2013.0024
   PubMed Web of Science ®Google Scholar
• Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383–390. doi:10.1586/14737140.2016.1162103
   PubMed Web of Science ®Google Scholar
• Mehta AA, Jose WM, Pavithran K, Triavadi GS. The role of gefitinib in patients with non-small-cell lung cancer in India. Indian J Palliat Care. 2013;19(1):48. doi:10.4103/0973-1075.110237
   PubMedGoogle Scholar
• Sequist LV, Piotrowska Z, Niederst MJ, et al. Osimertinib responses after disease progression in patients who had been receiving rociletinib. JAMA oncol. 2016;2(4):541–543. doi:10.1001/jamaoncol.2015.5009
   PubMed Web of Science ®Google Scholar
• Planchard D, Besse B, Groen HJ, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: updated 5-year survival rates and genomic analysis. J Thorac Oncol. 2021;2021:1.
   Google Scholar
• Cao SJ, Xu S, Wang HM, et al. Nanoparticles: oral delivery for protein and peptide drugs. Aaps Pharmscitech. 2019;20:1. doi:10.1208/s12249-019-1325-z
   Web of Science ®Google Scholar
• Lin CH, Chen CH, Lin ZC, Fang JY. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. Journal of Food and Drug Analysis. 2017;25(2):219–234. doi:10.1016/j.jfda.2017.02.001
   PubMed Web of Science ®Google Scholar
• Reddy MR, Gubbiyappa KS. Formulation development, optimization, and characterization of entrectinib-loaded supersaturable self-nanoemulsifying drug delivery systems. BioNanoScience. 2023;13(2):521–540. doi:10.1007/s12668-023-01094-1
   Web of Science ®Google Scholar
• Vitulo M, Gnodi E, Meneveri R, Barisani D. Interactions between nanoparticles and intestine. Int J Mol Sci. 2022;23(8):4339.
   PubMed Web of Science ®Google Scholar
• Liu C, Kou Y, Zhang X, Cheng H, Chen X, Mao S. Strategies and industrial perspectives to improve oral absorption of biological macromolecules. Expert Opin Drug Deliv. 2018;15(3):223–233. doi:10.1080/17425247.2017.1395853
   PubMed Web of Science ®Google Scholar
• Ahadian S, Finbloom JA, Mofidfar M, et al. Micro and nanoscale technologies in oral drug delivery. Adv Drug Delivery Rev. 2020;157:37–62. doi:10.1016/j.addr.2020.07.012
   PubMed Web of Science ®Google Scholar
• Viswanathan P, Muralidaran Y, Ragavan G. Nanostructures for oral medicine; 2017.
   Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C. 2016;60:569–578.
   PubMed Web of Science ®Google Scholar
• Razak A, Mohd Gazzali SA, Fisol A, et al. Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview. Cancers. 2021;13(3):400. doi:10.3390/cancers13030400
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression. Med Res Rev. 2012;32(6):1220–1262.
   PubMed Web of Science ®Google Scholar
• Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7:DTI–S12519. doi:10.4137/DTI.S12519
   Google Scholar
• Famta P, Shah S, Chatterjee E, et al. Exploring new horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms. Curr Res Pharmacol Drug Discovery. 2021;2:100054. doi:10.1016/j.crphar.2021.100054
   PubMedGoogle Scholar
• Robinson K, Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol. 2020;10:265. doi:10.3389/fonc.2020.00265
   PubMed Web of Science ®Google Scholar
• Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm. 2017;526(1–2):474–495. doi:10.1016/j.ijpharm.2017.05.016
   PubMed Web of Science ®Google Scholar
• Jiang L, Li X, Liu L, Zhang Q. Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer. Nanoscale Res Lett. 2013;8(1):1. doi:10.1186/1556-276X-8-66
   PubMedGoogle Scholar
• Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 2009;12(1):46–78. doi:10.18433/J3RC77
   PubMed Web of Science ®Google Scholar
• Hou J, Sun E, Zhang ZH, et al. Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles. Drug Deliv. 2017;24(1):261–269. doi:10.1080/10717544.2016.1245370
   PubMed Web of Science ®Google Scholar
• Amin H, Amin MA, Osman SK, Mohammed AM, Zayed G. Chitosan nanoparticles as a smart nanocarrier for gefitinib for tackling lung cancer: design of experiment and in vitro cytotoxicity study. Int J Biol Macromol. 2023;246:125638. doi:10.1016/j.ijbiomac.2023.125638
   PubMed Web of Science ®Google Scholar
• Amin H, Osman SK, Mohammed AM, Zayed G. Gefitinib-loaded starch nanoparticles for battling lung cancer: optimization by full factorial design and in vitro cytotoxicity evaluation. Saudi Pharm J. 2023;31(1):29–54. doi:10.1016/j.jsps.2022.11.004
   PubMed Web of Science ®Google Scholar
• Ruge CA, Kirch J, Lehr C-M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges. Lancet Respir Med. 2013;1(5):402–413. doi:10.1016/S2213-2600(13)70072-9
   PubMed Web of Science ®Google Scholar
• H. LW, Loo C–Y, Traini D, Young PM. Inhalation of nanoparticle–based drug for lung cancer treatment: advantages and challenges. Asian J Pharm Sci. 2015;2015:481–489.
   Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374–392. doi:10.1016/j.jconrel.2017.11.036
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697–705. doi:10.1046/j.1365-2125.1996.00493.x
   PubMed Web of Science ®Google Scholar
• Koushik O, Rao Y, Kumar P, Karthikeyan R. Nano drug delivery systems to overcome cancer drug resistance—a review. J Nanomed Nanotechnol. 2016;7(378):2.
   Google Scholar
• Storti C, Le Noci V, Sommariva M, Tagliabue E, Balsari A, Sfondrini L. Aerosol delivery in the treatment of lung cancer. Curr Cancer Drug Targets. 2015;15(7):604–612. doi:10.2174/1568009615666150602143751
   PubMed Web of Science ®Google Scholar
• Jyoti K, Pandey RS, Madan J, Jain UK. Inhalable cationic niosomes of curcumin enhanced drug delivery and apoptosis in lung cancer cells. Indian J Pharm Educ Res. 2016;50:S23–31.
   Web of Science ®Google Scholar
• Otterson GA, Villalona-Calero MA, Hicks W, et al. Phase I/II Study of inhaled doxorubicin combined with platinum-based therapy for advanced non–small cell lung cancerinhaled doxorubicin with iv chemotherapy for NSCLC. Clin Cancer Res. 2010;16(8):2466–2473. doi:10.1158/1078-0432.CCR-09-3015
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Eleftheriadou E, Sapardanis I, et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Investigational New Drug. 2012;30:1628–1640. doi:10.1007/s10637-011-9714-5
   PubMed Web of Science ®Google Scholar
• Lemarie E, Vecellio L, Hureaux J, et al. Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv. 2011;24(6):261–270. doi:10.1089/jamp.2010.0872
   PubMed Web of Science ®Google Scholar
• Larsen ST, Jackson P, Poulsen SS, et al. Airway irritation, inflammation, and toxicity in mice following inhalation of metal oxide nanoparticles. Nanotoxicology. 2016;10(9):1254–1262. doi:10.1080/17435390.2016.1202350
   PubMed Web of Science ®Google Scholar
• Driscoll KE, Costa DL, Hatch G, et al. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol Sci. 2000;55(1):24–35. doi:10.1093/toxsci/55.1.24
   PubMed Web of Science ®Google Scholar
• Pettit DK, Gombotz WR. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends in biotechnology. Trends Biotechnol. 1998;16(8):343–349. doi:10.1016/s0167-7799(98)01186-x
   PubMed Web of Science ®Google Scholar
• Patton JS, Brain JD, Davies LA, et al. The particle has landed—characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Delivery. 2010;23(S2):S71–87. doi:10.1089/jamp.2010.0836
   PubMedGoogle Scholar
• El-Sherbiny IM, El-Baz NM, Yacoub MH. Inhaled nano-and microparticles for drug delivery. Glob Cardiol Sci Pract. 2015;2015:2. doi:10.5339/gcsp.2015.2
   PubMedGoogle Scholar
• Wang X, Chen Q, Zhang X, et al. Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies. Int J Nanomed. 2018;13:4641. doi:10.2147/IJN.S166584
   PubMed Web of Science ®Google Scholar
• Park JY, Park S, Lee TS, et al. Biodegradable micro-sized discoidal polymeric particles for lung-targeted delivery system. Biomaterials. 2019;218:119331. doi:10.1016/j.biomaterials.2019.119331
   PubMed Web of Science ®Google Scholar
• Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022;14(13):2601. doi:10.3390/polym14132601
   PubMed Web of Science ®Google Scholar
• He S, Gui J, Xiong K, Chen M, Gao H, Fu Y. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases. J Nanobiotechnology. 2022;20(1):101. doi:10.1186/s12951-022-01307-x
   PubMed Web of Science ®Google Scholar
• Chenthamara D. Therapeutic efficacy of nanoparticles and routes of administration. Biomater Res. 2019;23(1):1–29.
   Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–4019. doi:10.1200/JCO.2013.54.5392
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non–small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011;29(17):2312. doi:10.1200/JCO.2010.31.7875
   PubMed Web of Science ®Google Scholar
• Fink TH, Huber RM, Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. J Thorac Oncol. 2012;7(9):1432–1439. doi:10.1097/JTO.0b013e318260de75
   PubMed Web of Science ®Google Scholar
• Huang TT, Parab S, Burnett R, et al. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther. 2015;26(2):82–93. doi:10.1089/hum.2014.100
   PubMed Web of Science ®Google Scholar
• Lu C, Stewart DJ, Lee JJ, et al. Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012;7(4):e34833. doi:10.1371/journal.pone.0034833
   PubMed Web of Science ®Google Scholar
• Ho YP, Au‐Yeung SC, To KK. Platinum‐based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev. 2003;23(5):633–655. doi:10.1002/med.10038
   PubMed Web of Science ®Google Scholar
• Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non–small-cell lung cancer: NCCTG and SWOG Study N0426. J Clin Oncol. 2010;28(4):614. doi:10.1200/JCO.2009.23.6406
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szcze Sna A, et al. First-line ate-zolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Kluger H, Weiss SA, Olszanski AJ, et al. Abstract CT089: phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Res. 2019;79(13_Supplement):CT089. doi:10.1158/1538-7445.AM2019-CT089
   Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369. doi:10.1200/JCO.20.00793
   PubMed Web of Science ®Google Scholar
• Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):1–23.
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.16723
   PubMed Web of Science ®Google Scholar
• Rimkus T, Sirkisoon S, Harrison A, Lo HW. Tumor suppressor candidate 2 (TUSC2; FUS-1) and human cancers. Discov Med. 2017;23(128):325.
   PubMed Web of Science ®Google Scholar
• Motswainyana WM, Ajibade PA. Anticancer activities of mononuclear ruthenium (II) coordination complexes. Adv Chem. 2015;2015:1–21. doi:10.1155/2015/859730
   Google Scholar
• Leijen S, Burgers SA, Baas P, et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Investigational New Drug. 2015;33:201–214. doi:10.1007/s10637-014-0179-1
   PubMed Web of Science ®Google Scholar
• Horinouchi H, Sekine I, Sumi M, et al. Long‐term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non‐small‐cell lung cancer. Cancer Sci. 2013;104(1):93–97. doi:10.1111/cas.12028
   PubMed Web of Science ®Google Scholar
• Gandara DR, Piperdi B, Walsh WV. A randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta®) and Erlotinib (Tarceva®) vs single agent pemetrexed (Alimta®) in patients with progressive or recurrent Non-Small Cell Lung Cancer (NSCLC).
   Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(25):2980–2987. doi:10.1200/JCO.2016.66.9929
   PubMed Web of Science ®Google Scholar
• June CH, Warshauer JT, Bluestone JA. Is autoimmunity the achilles’ heel of cancer immunotherapy? Nat Med. 2017;23(5):540–547. doi:10.1038/nm.4321
   PubMed Web of Science ®Google Scholar
• Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. J Nanomater. 2019 ;2019:1–26. doi:10.1155/2019/3702518
   Web of Science ®Google Scholar
• Desai N. Nanoparticle albumin-bound paclitaxel (Abraxane®). Albumin in medicine: pathological and clinical applications. 2016.
   Google Scholar
• Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):1–8. doi:10.1186/s13045-019-0818-2
   PubMed Web of Science ®Google Scholar
• Sharma P, Mehta M, Dhanjal DS, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019;309:108720. doi:10.1016/j.cbi.2019.06.033
   PubMed Web of Science ®Google Scholar
• Anderson CF, Grimmett ME, Domalewski CJ, Cui H. Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(1):e1586. doi:10.1002/wnan.1586
   PubMed Web of Science ®Google Scholar
• Hafeez MN, Celia C, Petrikaite V. Challenges towards targeted drug delivery in cancer nanomedicines. Processes. 2021;9(9):1527. doi:10.3390/pr9091527
   Web of Science ®Google Scholar
• Rasool M, Malik A, Waquar S, et al. New challenges in the use of nanomedicine in cancer therapy. Bioengineered. 2022;13(1):759–773. doi:10.1080/21655979.2021.2012907
   PubMed Web of Science ®Google Scholar
• Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9(1):1050–1074. doi:10.3762/bjnano.9.98
   PubMed Web of Science ®Google Scholar